New Influenza Vaccine Shows Benefits in Older Adults
A Phase 3 study published in The Lancet demonstrates the benefits of a new influenza vaccine for individuals over 65. The vaccine combines three established methods to enhance protection.
A novel influenza vaccine, combining three distinct approaches to enhance protection, has demonstrated significant benefits in older adults during a Phase 3 study. The findings were published in the prominent medical journal, The Lancet.
The study focused on individuals aged 65 and over, aiming to assess the efficacy and safety of the combination vaccine. The vaccine utilizes three separate strategies to bolster the immune response against influenza, a critical need for the elderly whose immune systems may be less robust.
CSL Seqirus, a business unit of CSL, developed the vaccine to address the need for improved influenza defense in the aging population. Traditional influenza vaccines often provide insufficient protection for this demographic, leaving them vulnerable to severe illness and complications.
With its publication in the scientific journal, the study results are now widely available to healthcare professionals. The findings are expected to influence future recommendations for influenza vaccination strategies in older adults.